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English Summary
A considerable number of drugs from different therapeutic classes have the ability to delay cardiac repolarization, 
an effect that is reflected on the electrocardiogram as prolongation of the QT interval and the appearance of 
abnormal T-waves. Drug-induced inhibition of specific cardiac potassium channels has been shown to be the 
underlying cellular mechanism for QT interval prolongation, changes in the morphology of the T-wave, and the 
development of life threatening cardiac arrhythmias. To date, drug-induced arrhythmia has consistently involved 
inhibition of the cardiac IKr potassium channel, which is encoded by the KCNH2 (hERG) gene. hERG mutations are 
also known to provide the pathogenic substrate for inhibition of the IKr channel in the congenital type 2 form of the 
long QT syndrome (LQT2). Patients with LQT2 are at risk for arrhythmia and sudden death, with about half of 
them sustaining major arrhythmic events.
Proarrhythmic liability of drugs is one of the most common reasons for labeling restrictions and withdrawals of 
drugs from the market today. As a consequence, assessing the potential for a new drug to cause life-threatening 
arrhythmias is now an integral component of premarketing safety assessment. The corner stone of this assessment
is
effect on cardiac repolarization. This study calls for careful evaluation of drug effects on the QT interval to exclude 
proarrhythmic risk associated with a drug.
But there is a problem...QT interval prolongation is an inadequate marker of abnormal repolarization and a poor 
predictor of drug-induced arrhythmias.
The purpose of this thesis has, therefore, been to advance the presently inadequate characterization of drug-induced 
abnormal repolarization under the conjecture of a central role of hERG encoded IKr channel inhibition as the 
repolarization altering mechanism that can lead to proarrhythmia. Phenotypical ECG characteristics of the
congenital LQT2 syndrome were used as computerized measures of T-wave morphology to indicate drug-induced 
repolarization abnormalities.
Four different IKr inhibiting drugs with different proarrhythmic potential were studied and their effects on T-wave 
morphology were compared to the effects on the QT interval. It was shown that there is a close relationship 
between drug influence and the development of specific LQT2-like T-wave morphology, which is consistent with 
the underlying cellular electrophysiology of IKr inhibition caused by the various drugs investigated in this work.
Drug effects on T-wave morphology could be several times greater  than  the effects on the QT interval and this 
difference was positively related to the supposed proarrhythmic potential of the investigated drugs. It was further 
demonstrated that computerized analysis of LQT2-like T-wave morphology, may provide an opportunity to identify 
and explore complex drug effects on cardiac repolarization that cannot be described by the QT interval alone.
Finally, it was shown that the relationship between QT interval prolongation and a change in T-wave morphology 
is very different for drugs with different risk profiles. Collectively, this work offers new insights into the 
characterization of drug-induced repolarization abnormalities that may lead to improved
proarrhythmic potential.
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Dansk Resumé
Et betragteligt antal lægemidler fra forskellige terapeutiske klasser har den egenskab at de forsinker hjertets 
repolarisering, en effekt der reflekteres på elektrokardiogrammet som et forlænget QT interval og forekomsten af 
abnormale T-takker. Det er påvist at lægemiddel-inhibering af specifikke kaliumkanaler i hjertet er den cellulære 
mekanisme, der ligger til grund for QT interval forlængelse, ændringer i morfologien af T-bølgen og udviklingen af 
livstruende hjertearytmier. Lægemiddel-induceret hjertearytmi har til dato konsekvent involveret inhibering af 
hjertets IKr  kanal, som KCNH2 (hERG) genet koder for. hERG mutationer er også kendt for at være det patogene 
grundlag for inhibering af IKr kanalen i den medfødte type 2 form af langt QT syndrom (LQT2). Patienter med 
LQT2 er i fare for hjerteartymi og pludselig død og omkring halvdelen af dem oplever betydelige hjertearytmier.
Proarytmisk risiko for lægemidler er en af de mest almindelige årsager til restriktioner på labels og 
tilbagetrækninger af lægemidler fra markedet i dag. Følgelig er vurdering af et nyt lægemiddels evne til at forårsage 
livstruende hjertearytmier blevet en integreret del af premarketings sikkerhedsvurdering. Hjørnestenen i denne 
vurdering, er et klinisk fase I studie som har til hensigt at identificere lægemidler der 
har en farmakologisk effekt på hjertets repolarisering. Dette studie opfordrer til grundig evaluering af
medicinpåvirkninger af QT intervallet, for at kunne ekskludere proarytmisk riskio forbundet med et lægemiddel.
QT interval forlængelse er en utilstrækkelig markør for abnorm repolarisering og er dårlig 
til at forudsige om et lægemiddel vil inducere arytmier.
Formålet med denne afhandling har derfor været, at avancere den nuværende utilstrækkelige karakterisering af 
lægemiddel-induceret abnorm repolarisering, under formodning om en central rolle for hERG kodet IKr kanal 
inhibering som den repolariserings-forandrende mekanisme, der kan føre til hjertearytmi. Fænotypiske EKG 
kendetegn for medfødt LQT2 syndrom blev anvendt som computeriserede mål for T-bølge morfologi til at indikere 
lægemiddel-inducerede repolariserings abnormaliteter.
Fire forskellige IKr inhiberende lægemidler med forskellig proarytmisk potentiale blev studeret og deres effekter på 
T-bølge morfologi blev sammenlignet med deres effekter på QT intervallet. Det blev vist, at der var en tæt
sammenhæng mellem lægemiddelpåvirkning og udviklingen af specifik LQT2-agtig T-bølge morpfologi som er 
forenelig med den cellulære elektrofysiologi der ligger til grund for IKr inhibering forårsaget af de forskellige 
lægemidler der blev undersøgt i dette arbejde. Medicinpåvirkning af T-bølge morfologi kunne være adskellige
gange større end påvirkninger på QT intervallet og denne forskel var positivt relateret til det formodede
proarytmiske potentiale for de undersøgte lægemidler. Det blev desuden demonstreret at computeriseret analyse af 
LQT2-agtig T-bølge morfologi, kan gøre det muligt at identificere og opdage komplekse medicinpåvirkninger af 
hjertets repolarisering, som ikke kan beskrives med QT intervallet alene. Slutteligt blev det vist, at sammenhængen 
mellem QT interval forlængelse og en ændring af T-bølge morfologi, er meget forskellig for lægemidler med 
forskellige risikoprofiler. Samlet set giver dette arbejde nye indblik i karakteriseringen af lægemiddel-inducerede 
abnormaliteter der kan føre til bedre forudsigelse af et lægemiddels proarytmiske potentiale
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INTRODUCTION
THE CLINICAL PROBLEM
ore than one hundred years after Einthoven 
recorded his first electrocardiogram (ECG), 
cardiac repolarization is not completely understood. 
Clinicians and researchers keep debating the cellular 
basis of repolarization and are still learning how to 
extract information about the repolarization process 
from the ECG.
One of the parameters in the surface ECG that 
describes repolarization is the QT interval. The QT 
interval and changes in the QT interval may seem to 
be related to cellular processes in a simple way: the 
action potential duration (APD) defines the QT 
interval and QT prolongation, therefore, is an 
indicator of increased APD. However, the truth is 
more complex. Myocardial cells from different parts 
of the heart, even from different layers of the 
muscular wall have different APDs and may respond 
differently to external factors, such as drugs, making 
the repolarization process more heterogeneous.
Adding to the complexity is the coupling of the cells 
in situ, which also has a great, but poorly quantified,
influence on their relative APDs.
QT prolongation has attracted a great deal of attention 
because of its apparent association with life-
threatening cardiac arrhythmias such as Torsades de 
Pointes (TdP).
1
This arrhythmia refers to a rapid and 
irregular polymorphic ventricular tachycardia that was 
first described by Dessertenne in 1966.
2
It is 
characterized by an electrocardiographic pattern of 
continuously changing morphology of the QRS 
complexes that seem to twist around an imaginary 
baseline. Torsade is commonly non-sustained but can 
lead to syncope and may degenerate into ventricular 
fibrillation and sudden death. The likelihood of TdP is 
increased in a milieu of heterogeneous ventricular 
repolarization
1,3
and the arrhythmia usually occurs in 
the setting of T-wave abnormalities, increased U-
wave amplitudes and an excessively prolonged heart 
rate corrected QT interval (QTc).
4,5
A prolonged QT interval and the concomitant risk for 
TdP is the hallmark of the various congenital long QT 
syndromes but may also be induced by several drugs.
To date, drug-induced TdP has consistently involved 
inhibition of the cardiac IKr channel.
6
The APD 
prolongation in this case is caused by a reduced rate of 
potassium ions through the IKr channels, which are 
encoded by the KCNH2 (hERG) gene.7 It was found8
that IKr inhibition is involved in one of the most 
common forms of congenital long QT syndrome 
(LQTS) type 2 and affected by a large number of 
cardiac and non-cardiac drugs as well.
6
QT interval prolongation and the proarrhythmic 
liability of drugs has become one of the most common 
reasons for labeling restrictions and withdrawals of 
drugs from the market.
9,10
The first drug to be 
withdrawn from the market due to cases of arrhythmia 
was prenylamine in 1988. Many more withdrawals,
restrictions, and denied market authorizations have 
since followed for a range of drugs that belong to 
different pharmacological classes including the drugs
terodiline, astemizole, cisapride, lidoflazine, 
droperidol, levomethadyl, grepafloxacin, 
mesoridazine, sparfloxacin, terfenadine, thioridazine, 
and sertindole. In recent decades, the US Food and 
Drug Administration (FDA) has expanded its 
requirements for drug testing. Today, a new drug 
requires an average of 15 years in research and 
development to reach the market and the cost was 
estimated to be as high as 1.7 billion US dollars.
11
Still, only 1 in 10 drugs that enter clinical testing are 
approved by the FDA and the failure rate for drugs in 
phase III has increased.
12
This poor state of drug 
development was addressed in a white paper known as 
the Critical Path Initiative.
13
The report concluded that 
the major contributor to the inefficiency in 
development of drugs was the absence of innovative 
new methods for preclinical and clinical testing of 
drugs:
Not enough applied scientific work has been done to 
create new tools to get fundamentally better answers 
about how the safety and effectiveness of new 
products can be demonstrated, in faster time frames, 
with more certainty, and at lower costs. In many 
cases, developers have no choice but to use the tools 
and concepts of the last century to assess this 
century's candidates .
Such dilemmas pose obvious challenges for drug 
developers who are searching for ways to expedite the 
drug discovery and evaluation processes while at the 
same time developing safe drugs. As a consequence, it
has now been emphasized by the FDA that efforts 
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must be directed towards the development of new 
biomarkers that can improve the prediction of cardiac 
toxicity.
14
In addition to the Critical Path document, the FDA 
together with Health Canada released another paper in 
2002 that provided the drug development industry 
with a preliminary guidance on the importance of 
ECG analysis for drug approval.
15
This concept paper 
was subsequently subjected to the International 
Committee on Harmonization (ICH), which 
culminated in 2005 with the acceptance of the E14 
Guidance for clinical evaluation of QT interval 
prolongation and proarrhythmic potential of non-
antiarrhythmic drugs .
16
The corner stone of the 
guidance was the establishment of a clinical phase I 
confidently identify drugs that have a threshold 
pharmacologic effect on cardiac repolarization. This
study is presently a required integral part of the 
development of practically every pharmaceutical 
compound.
THE THOROUGH QT STUDY -
REGULATORS ANSWER TO THE PROBLEM
The goal of the Thorough QT study (TQTS) is often 
misunderstood. This study is not aimed at quantifying 
the risk of drug-induced TdP. Rather, the purpose of 
this study is to exclude proarrhythmic risk associated 
with a drug by establishing whether the investigated 
drug has any effect on cardiac repolarization, which is 
the potential basis of drug-induced TdP. 
The primary end point in the TQTS is the drug-
induced QTc change from baseline corrected for 
placebo effects. Regulatory guidance on how much 
QTc prolongation might be related to risk of TdP 
mainly reflects the experience with
approving QTc prolonging drugs and observing their 
effect on the market over the past 20 years. The 
consensus of the relationship between QTc 
prolongation and risk is the following: 0-5 ms imparts 
no risk; if the QTc prolongation is greater than 20 ms 
the risk for TdP is considered elevated or quite high. It 
is further suggested that a 5-10 ms QTc prolongation
is of minimal concern and that the risk associated with 
a 10-20 ms effect is uncertain.
16
The TQTS also involves the reporting of 
electrocardiographic abnormalities of the morphology 
of the ECG. Specifically, such assessments should be 
described and presented in terms of the number and 
percentage of subjects in each treatment group who 
manifest the appearance or worsening of a 
morphological abnormality. Particular attention 
should be directed to the appearance of abnormal U-
waves and changes in T-wave morphology that might 
be indicative of delayed repolarization such as double 
humps or notched T-waves, indistinct terminal TU 
complex, delayed inscription or prolonged ST 
segment, widening, flattening and inversion.
16
The TQTS is carried out in healthy volunteers to 
provide indications of QTc prolongation in the target 
population of patients to be studied during later phases 
of drug development. The design can be parallel or 
cross-over depending on the half-lives of the parent 
compound or metabolites and should be randomized 
and placebo-controlled. In addition, an active control 
should be used to demonstrate that the study can 
discern the level of QT prolongation which is of 
regulatory concern. In the overwhelming majority of 
studies, a single 400 mg dose of moxifloxacin has 
been used because this drug has a relatively consistent 
and mild QTc prolonging effect and is considered to 
have a safe cardiovascular profile.
The study is typically performed after significant 
information is available on the pharmacokinetics of 
the compound. This is because the number and timing 
of ECG recordings taken after each dose of the study 
drug is driven mainly by the pharmacokinetic and 
pharmacodynamics properties of the drug. Ideally, the 
time points for ECG recordings should be chosen 
based on the expected time course of drug related QTc 
change from baseline so that recordings can be 
obtained at times around the expected peak plasma 
concentrations.
The sample size of the TQTS is defined by the 
requirement of having enough power to detect a 5 ms 
change from baseline because this level is considered 
the magnitude of QTc prolongation where risk begins.
The study is expected to be able to discern this small 
degree of QTc prolongation with 80% power and a 
0.05 level of significance. For the results of the TQT 
study to be most predictive all sources of variability 
must be controlled because a key determinant of 
sample size is the variance of QTc changes from 
baseline which in large part is determined by the 
number of subjects included in the study and to some 
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degree by the number of ECGs recorded per subject. 
The typical TQTS usually enrolls 40 to 60 subjects 
and include 10.000 to 15.000 ECG recordings. An 
outlier or categorical analysis in the TQTS is 
explorative because the study is not powered to 
accurately detect the number of subjects who respond 
in an exaggerated manner.
It is generally assumed that if a drug truly prolongs 
the QT interval it will be dose related. This is why the 
TQTS typically looks at the effect on QTc 
prolongation of both therapeutic and supratherapeutic 
doses of a drug. The study should reflect situations in 
which plasma levels may be markedly elevated in the
target population and the supratherapeutic dose level 
is intended to achieve the highest exposure levels 
anticipated in clinical practice, e.g. exposure levels 
caused by drug-drug interactions, overdose, genetic 
polymorphisms affecting drug metabolism, or in 
patients with heart disease.
The outcome of a TQTS is classified as negative if the 
upper limit of the two-sided 90% confidence interval 
for the largest time-matched difference between the 
test drug and placebo is below 10 ms.
16
This level of 
QTc prolongation is chosen to provide reasonable 
assurance that the mean effect of the study drug on 
QTc prolongation is not greater than around 5 ms. If
the upper limit of the two-sided 90% confidence 
interval for QTc prolongation exceeds 10 ms, then the 
test drug is declared positive. In other words, the drug 
is classified as having affected cardiac repolarization.
The outcome of the TQTS has severe implications for 
a drug development program. A negative study will 
almost always allow drug development to proceed 
without any dedicated focus on QT assessments. A
positive study on the other hand would imply more 
complex additional and expensive monitoring of QTc 
effects, dose concentration responses and drug 
interactions in a substantial number of patients in the 
target population. Thus, a positive study is expected to 
result in a need to collect a significant number of 
ECGs during the later phases II and III of clinical 
testing. This extensive pre-market ECG testing and 
possibly additional post-market monitoring is 
extremely costly and may render the drug 
economically non-viable.
The thorough QT study has attained such a pivotal 
role in drug testing that it can mean the difference 
between continuation and termination of a drug 
development program. In light of the implications for 
drug developers of the outcome of the TQTS it is 
important that the study provides the correct guidance.
As a whole, the pharmaceutical industry 
acknowledges the importance of the TQTS but drug 
developers are also rightfully skeptical of conclusions 
based on the measurement of the QT interval because 
this measurement by is increasingly regarded as a 
poor surrogate marker of the risk of proarrhythmic 
events.
Important design and measurement issues of the 
TQTS are continuously debated and it can be expected 
that changes will be made to the way these studies are 
conducted. At present it is likely however that the 
implementation of the TQTS will result in an 
increasing number of drugs with label statements with 
regard to QT prolongation based on TQTS outcomes 
that exceed the regulatory threshold. Such labeling is 
already in effect. The drug alfuzosin, which does not 
inhibit the IKr channel at anywhere near relevant 
concentrations, and which has not been associated 
with proarrhythmia after extensive post-marketing 
experience, but which produces a small QTc 
prolongation somewhat exceeding 10 ms in a TQT 
study
17
, now bears a label with warnings of cardiac 
repolarization effects.
THE QT INTERVAL -
A BIOMARKER PROBLEM
The first collection of challenging problems faced by 
clinicians, regulators and drug developers is related to 
the task of measuring the QT interval with precision. 
The measurement problem has existed for more than 
five decades, since the QT interval was first measured 
using paper ECG recordings and remains largely 
unsolved today with the increasing use of digital 
recordings. Challenges relate to a number of factors, 
but the most frequently cited difficulties consist of 
delineating the end of the T-wave when this wave is 
flat, bifid, biphasic, broad, notched or overlapping 
with a U-wave. Indeed, measurement of the QT 
interval may lead to quite significant differences 
depending on the experience of the reader.
18
The utilization of QT interval measurements may also 
be complicated in the presence of heart rate changes. 
When the heart rate decreases or increases, the QT 
interval prolongs or shortens, respectively, even 
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without any drug intervention. Because of this inverse 
relationship with heart rate, it is customary to obtain a 
heart rate corrected QT interval. However, despite 
numerous attempts to derive a universally acceptable 
formula for heart rate correction of the QT interval, 
the problem has not been resolved. The QT interval 
has been corrected for heart rate using a number of 
methods including fixed population formulas, data 
driven formulas derived from the population under 
investigation or individual correction methods.
19
Problems such as over or under correction are known 
to exist for fixed population methods and there is 
increasing evidence that the relationship between the 
QT interval and heart rate is subject-specific.
19
Unfortunately, the effective use of subject-specific 
correction methods can present important problems in 
clinical trials because subjects are at rest during the 
ECG recordings, usually with little variation in their 
heart rates. In such situations, an individually derived 
correction method, based on a narrow range of heart 
rates, may be incorrect. The data driven population 
based methods on the other hand, rely on the
assumption that the relationship between the QT 
interval and heart rate is the same for all subjects and 
that a single model properly describes this 
relationship, which is incorrect.
Correction of the QT interval for heart rate has been 
the subject of intense debate for almost a century 
Needless to say, issues surrounding the choice of the 
most appropriate heart rate correction method are 
rather complex. Today, there are over 30 different 
formulas for heart rate correction of the QT interval
20
and all of them yield different QTc values. The search 
for refined heart rate correction methods is likely to 
continue although it has been argued that this 
technical discussion may have limited physiological 
meaning
21
and that further studies aiming at finding 
counterproductive.
22
The second set of challenges is that, in terms of 
cardiovascular safety, the ability of QT interval 
measurements to predict TdP is unclear. Early work 
suggested a simple relationship between the degree of 
QT prolongation and proarrhythmia with a 5% 
increase in baseline risk of proarrhythmic events for 
every 10 ms increase in the QT interval.
23
Although 
attractive, this correlation is now known to be an 
oversimplification of a much more complex
relationship between the QT interval and 
cardiovascular risk. There are numerous experimental
and clinical studies showing compelling evidence that 
the QT interval is a poor surrogate marker of 
proarrhythmic susceptibility, and there are many 
shortcomings to the assumption of a simple QT-
proarrhythmia relationship.
2,24-26
Different drugs 
causing comparable absolute or relative increases in 
the QT interval do not result in similar TdP incidences 
(e.g. sotalol versus dofetilide or amiodarone versus 
almokalant). In serial experiments with different doses 
of the same drug, proarrhythmia has been shown not 
to depend on the degree of QT interval 
prolongation.
27,28
Altering drug infusion rates can 
change the incidence of TdP without affecting the QT 
interval.
29,30
Sotalol can induce arrhythmia before any 
prolongation of action potentials is observed in 
cardiac cells.
31
It is generally estimated that about 10-
20% of otherwise healthy individuals have borderline 
QTc values beyond the so called normal range
32
and 
among the congenital syndromes, associated with 
abnormal repolarization, the short QT syndrome poses 
the greatest risk.
In light of such obvious limitations in characterizing 
abnormal repolarization, it is difficult to understand 
why this measurement would be regarded an 
indispensible and essential electrocardiographic 
biomarker for drug safety assessment. Nevertheless, 
presently there are no other established methods.
There is little doubt however, that further 
understanding of the cellular and molecular 
mechanisms underlying repolarization will enable us 
to develop better indices of repolarization 
abnormalities and that such biomarkers will improve 
prediction of drug-induced proarrhythmic potential.
T-WAVE MORPHOLOGY -
ADRESSING THE QT BIOMARKER PROBLEM
Much of our current knowledge about drug-induced 
ion channel defects has been influenced by our 
knowledge of the congenital long QT syndrome. 
There are several types of the congenital long QT 
syndrome, including type 2 (LQT2) which is caused 
by loss-of-function mutations of hERG
8
and is the 
second most prevalent form of this syndrome. The 
human ether related a go-go gene (hERG) encodes the 
IKr channel responsible for the repolarizing current in 
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the cardiac action potential and patients with LQT2 
are at risk for TdP and sudden death
33
, with about half 
of them sustaining major arrhythmic events.
Observations from ECG analysis in patients with 
congenital long QT syndrome have revealed that 
specific genetic forms are associated with distinctive 
T-wave morphologies.
34-37
Of particular interest here, 
are the patterns described for LQT2, which include 
flat, bifid, notched and low amplitude T-waves. 
Interestingly, the hERG channel appears to be the 
most pharmacologically promiscuous among all 
known voltage-gated potassium channels, with drugs 
from a wide range of therapeutic categories capable of 
inhibiting the channel.
38,39
Hereby, the unique position 
of hERG and the IKr channel is highlighted as the 
common denominator
40
in congenital and drug-
induced long QT syndrome. It is therefore not 
surprising that electrocardiographic abnormalities 
similar to those seen in patients carrying mutations in 
the hERG gene can be produced via direct blockade of 
hERG/IKr channels by a large group of diverse 
therapeutic compounds including many 
antiarrhythmics, antihistamines, antipsychotics and 
antibiotics. In fact, profound T-wave morphology 
changes have been seen with drugs that inhibit the IKr
channel and the severity of these changes has been 
shown to be more pronounced in patients who develop 
TdP.
41
The electrophysiological effect of IKr inhibition has 
been studied both in experimental systems, where all 
cell types are represented
42,43
, and using computer 
models in which the effects of individual action 
potential currents can be simulated.
44
These studies 
have demonstrated that there are significant 
differences in repolarization in the various layers of 
the myocardium, with the epicardial cells having the 
shortest action potential duration, endocardial cells 
having an intermediate duration, and M cells having 
the longest action potential duration. This 
physiological transmural dispersion of repolarization 
usually does not lead to TdP. However, in both the in 
vitro and in silico work, IKr inhibition prolongs the 
action potential of M cells substantially, while 
endocardial and epicardial action potentials show 
much smaller changes. Such IKr related differential 
effects can give rise to exaggerated transmural 
dispersion which in turn increases the susceptibility to 
reentry, a mechanism presumed to underlie TdP. 
Physiologically, there is a substantial degree of spatial 
dispersion in repolarization, not only across the 
myocardial wall but also between the apex and base of 
ventricles, between the septum and free walls, as well 
as between the left and right ventricles. It is not 
known whether heterogeneity between apex and base 
or between left and right ventricles are similar to those 
observed for transmural dispersion, although it seems 
likely due to the different distribution of 
repolarization channels in cells of these regions. 
Prolongation of the QT interval can result from both 
homogeneous and heterogeneous prolongation of the 
predominant myocardial cell types. It is therefore
possible that electrocardiographic assessment of drugs 
using QT interval as the only marker of repolarization,
could overlook the effect of dispersion which appears 
to be a necessary substrate for inducing TdP. In fact, 
this may be one explanation for the lack of a clear 
correlation between QT interval prolongation and 
proarrhythmia. In contrast, T-wave patterns such as 
those seen in LQT2 are thought to result from a 
heterogeneous repolarization of the predominant 
myocardial cell types, which is claimed to be 
associated with more proarrhythmic potential than 
homogeneous repolarization. 
Drug-induced IKr inhibition can also cause 
triangulation of the action potential with loss of notch-
and-dome morphology replaced by a linear phase 
repolarization. Triangulation is reported to be a strong 
predictor of proarrhythmia and to appear on the ECG 
as a widened, flattened or notched T-wave.
45
Interestingly, triangulation may be accompanied by 
either shortening or lengthening of the cardiac action 
potential duration which indicates that drug-induced 
T-wave morphology changes may be independent of 
QT interval measurements. 
In conclusion, drug-induced myocardial heterogeneity 
may manifest, not only as differences in action 
potential durations, but also as changes of action 
potential shapes. Importantly, both cellular 
phenomena translate directly into characteristic 
changes of T-wave morphology that are distinctive of 
congenital LQT2. It appears that there are many 
components to cardiac repolarization beyond just its 
duration and that there is information to be gained 
about cardiac repolarization from the analysis of T-
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wave morphology changes in drug studies, which goes 
beyond the information that can be obtained from 
measurements of the QT interval. For this reason it 
would be important to quantify T-wave manifestation
of the cellular mechanisms in drug studies instead of 
merely estimating the end of the T-wave to measure 
the QT interval. 
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PURPOSE OF THIS THESIS
The purpose of this thesis has been to advance the presently inadequate electrocardiographic characterization of 
drug-induced abnormal repolarization, under the conjecture of a central role of KCNH2 (hERG) encoded IKr
channel inhibition as the repolarization altering mechanism that can lead to proarrhythmia.
The principal ion channel affected by most proarrhythmic drugs is IKr, which is the same channel affected in LQT2 
patients with loss-of-function hERG mutations. Therefore, this work has attempted to determine whether 
phenotypical ECG observations in the congenital LQT2 syndrome could be used as computerized measures of T-
wave morphology to indicate drug-induced repolarization abnormalities. 
The degree of QT interval prolongation is currently considered the gold standard for assessment of abnormal 
repolarization. This work has therefore further aimed to discover whether a change of T-wave morphology 
represents a more pronounced manifestation of drug-induced repolarization abnormality than prolongation of the 
QT interval, because this property would be constructive to expanding electrocardiographic safety evaluation of 
drugs in clinical trials.
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CONCLUSION
This study has investigated the possibility of 
advancing the presently inadequate 
electrocardiographic characterization of drug-induced 
repolarization abnormalities, using phenotypic ECG 
observations in the congenital LQT2 syndrome as 
computerized measures of T-wave morphology. This 
work has further aimed to discover whether a change 
of T-wave morphology represents a more pronounced 
manifestation of drug-induced repolarization 
abnormality than prolongation of the QT interval.
Such a property would be constructive to expanding 
electrocardiographic safety evaluation of drugs in 
clinical trials.
Considerable evidence has been provided that a 
composite marker of asymmetry, flatness and notches, 
which represent typical T-wave patterns indicative of 
abnormal repolarization in the congenital LQT2
syndrome, could be used as a sensitive indicator of 
abnormal repolarization induced by drugs. It was 
shown that such T-wave morphology characteristics 
could be used to identify repolarization abnormalities 
due to a variety of drugs belonging to different 
therapeutic classes, and also across a broad spectrum 
of drug-induced shape changes, from subtle to 
exceedingly pronounced. This study offers new 
insights into the effects of drugs on repolarization and 
suggests added benefits of using a composite T-wave 
morphology score for cardiovascular risk stratification 
in combination with the assessment of the QT 
interval.
ECG EXPRESSION OF DRUG EFFECTS
After administration of the drugs used in the studies, 
there was typically a clear increase in the flatness and 
the asymmetry of the T-wave and often notches in the 
T-wave occurred. The drug-induced changes were 
similar to the differences seen between healthy 
subjects and patients with the LQT2 syndrome. These 
T-wave features are the hallmarks of severely 
abnormal repolarization that has often been linked to 
TdP arrhythmia. Notched T- waves are also included 
as a morphology characteristic in the diagnostic 
criteria for the congenital Long QT syndrome. These
T-wave characteristics were not seen in subjects prior 
to drug administration and remained absent with 
placebo treatment. The development of notches on the 
T-wave was more frequently associated with 
administration of drugs that have substantial or 
apparently elevated torsadogenic potential such as d,l-
sotalol and sertindole, respectively. 
Each of the individual LQT2 markers that were 
investigated, including their combined overall 
expression of T-wave morphology, developed 
concurrent with blood plasma concentrations of the 
drug. It was further demonstrated that such 
morphology patterns were dose dependent and that the 
T-wave characteristics showed an accumulation over 
days when dosing to a steady state.
Combined, the results imply that there is a close 
relationship between drug influence and the 
development of specific LQT2-like T-wave 
morphology patterns, which is consistent with the 
underlying cellular electrophysiology of IKr inhibition 
caused by the various drugs investigated in this work. 
These observations also support the conjecture that
the T-wave patterns that are indicative of abnormal 
repolarization in the congenital LQT2 syndrome, can
be used as, electrophysiologically motivated, indices 
to quantify the degree of drug-induced repolarization 
abnormalities. This finding advocates further research 
into the possibility of using quantitative T-wave 
morphology to categorize drugs, not only by the 
degree of drug-induced abnormal repolarization, but,
more importantly, by their proarrhythmic potential. In 
addition, LQT2-like patterns of T-wave morphology 
may be used in pharmacological stress testing to 
uncover latent repolarization disorders and as
guidance for genotyping of people with suspected 
long QT syndrome.
CONSISTENCY OF DRUG EFFETCS
The administration of drugs often led to prominent 
changes of T-wave morphology, in some cases 
without concomitant prolongation of the QTcF 
interval. The average subject had drug-induced 
repolarization abnormalities that were easier to 
discriminate from baseline by the degree of T-wave 
morphology changes than by QTcF prolongation. 
Following drug treatment, subjects with a shorter 
QTcF interval on baseline tended to respond with a 
larger prolongation of the repolarization interval than 
patients with longer baseline QTcF values. This 
tendency was not seen for T-wave morphology. 
Drug-induced T-wave Abnormalities: Beyond QTc 
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In general, the drugs, and in particular those 
associated with high risk of inducing arrhythmia, 
appear to have a more consistent effect on T-wave 
morphology than on QTcF prolongation. From a 
clinical perspective, this favorable property of T-wave 
morphology analysis could be useful during 
electrocardiographic monitoring of patients taking 
certain QT prolonging drugs. Monitoring of the QT 
interval is already mandatory for some drugs. 
However, the QT interval may fail to identify all 
subjects with an increased risk of developing 
arrhythmia and it would, therefore, be relevant to 
extend electrocardiographic monitoring to also 
include evaluation of drug-induced T-wave 
morphology changes.
The implications for thorough QT studies, of a 
consistent identification of drug-induced 
repolarization changes are obvious. The thorough QT
study relies on identification of drug-induced QTc 
change from baseline as the primary end point, and 
given the low threshold for regulatory concern, the 
possibility exists that incorrect conclusions will be 
drawn about the cardiovascular safety of a drug. The 
thorough QT study also investigates categorical 
responses, which in the case of inconsistent 
recognition of drug effects would render this type of
analysis less useful. There are also potential problems 
associated with the QT prolongation being a skewed 
function of baseline QT interval, which was found to 
exist for drug-induced prolongation of QTcF but not 
for changes in T-wave morphology. This concern 
relates to violation of the assumption of a
homogeneous drug response underlying the statistical 
analyses typically performed in the thorough QT
studies. Differential drugs responses could jeopardize 
the sensitivity and validity of these statistics and
propensity to alter cardiac repolarization. 
MAGNITUDE OF DRUG EFFECTS
The changes in T-wave morphology were shown to be 
more pronounced manifestations of drug-induced 
repolarization abnormalities than QT interval 
prolongation. Drug effects on T-wave morphology 
could be larger for individual subjects, for mean 
estimates around the time of peak plasma 
concentrations, and for the maximum time-matched 
change from baseline, which is the primary end point 
in drug trials. Drug effects could be more than 10 
times greater for T-wave morphology compared to the 
effects on QT interval prolongation and this factor
was positively related to the supposed torsadogenic 
potential of the investigated drugs. A low drug dose of
a torsadogenic drug could have the same effect on T-
wave morphology as a higher dose of the drug would 
have on QT interval prolongation. No changes in T-
wave morphology were induced by placebo treatment. 
Collectively, these findings highlight the importance 
extending electrocardiographic analysis of drug 
effects to the entire repolarization segment instead of 
merely using the end of the T-wave to measure the QT 
interval. The literature clearly indicates that an 
increase in local and/or global heterogeneity, i.e. 
transmural, apex-base, left-right, of the repolarization 
process in the heart is associated with an increased 
risk of arrhythmia. The QT interval does not reflect 
any of this heterogeneity, whereas the shape of the T 
wave is directly affected by it. This aspect of 
repolarization is thus better captured by changes in T-
wave morphology than by prolongation of the QT 
interval. Surely, this property of T-wave morphology 
extends favorably to investigation of repolarization 
effects and assessment of cardiac safety in clinical 
studies of new drugs. Indeed, it was shown that the 
use of T-wave morphology in drug trials would
increase statistical power or, alternatively, would
reduce the cost of conducting such trials by enrolling 
fewer subjects. At the same time, T-wave morphology 
may also be used in drug studies for categorical 
analysis to indicate exaggerated response in subjects 
with a reduced repolarization reserve. 
COVARIATE DRUG EXPRESSIONS
This work has demonstrated that computerized 
analysis of LQT2-like T-wave patterns, may be used
to identify and explore complex drug effects on 
cardiac repolarization that cannot be described by the 
QT interval alone. It has been shown that drugs with 
different torsadogenic potential can induce 
significantly different changes in T-wave morphology 
for a given QT interval prolongation. Moreover, it was
shown that the relationship between QT interval 
prolongation and changes in T-wave morphology is 
very different for drugs with different risk profiles.
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More pronounced T-wave morphology changes were 
seen at similar QT interval prolongations for drugs 
with a supposedly higher proarrhythmic risk.
These findings may add to our understanding of why 
drugs, which prolong the QT interval to the same 
extent, can have different incidences of arrhythmia 
and, vice versa, why drugs, associated with a similar 
incidence of arrhythmia do not necessarily prolong the 
QT interval to an equivalent degree. 
Certainly, the assumption that a given threshold for 
QT interval prolongation is indicative of a certain risk 
is not correct. A covariate description of drug-induced 
changes, which includes both T-wave morphology 
and QT interval prolongation, may be important for
clinical trials for cardiac safety assessment of new 
drugs. Using this covariate approach it may be 
possible to address the shortcomings of the 
assumption of a simple QT-proarrhythmia 
relationship. Most notably, it may be possible to 
characterize drugs with similar QT interval prolonging 
effects as having different torsadogenic potential. 
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